Vical Reports Second Quarter 2014 Financial Results and Progress in Key Development Programs

Vical Reports Second Quarter 2014 Financial Results and Progress in Key Development Programs

Biography Sean Sullivan is Executive Director of Pharmaceutical Sciences at Vical, Incorporated. Allied noted that it currently has sufficient capital to achieve its major milestones, including the initial approval and launch of CardioCel® and the start of the first clinical study for the Herpes vaccine program with Professor Ian Frazer’s Coridon group in which Allied has 46.8% interest. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections. for expenses related to the development of ASP0113 (TransVax™), Vical’s therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients. In 2011, Vical received a $25.0 million upfront license payment from Astellas. The company’s first quarter 2013 net cash use was consistent with the company’s prior guidance for the full year. Vical had cash and investments of $49.1 million at December 31, 2014.

ASP0113 has received orphan drug designation in the United States and Europe for the prevention of CMV disease in HCT and SOT patients. The first two dose escalation cohorts are fully enrolled and dosed. 5:32 pm Medidata Solutions signs multi-year enterprise deal with Hanmi Pharmaceutical (MDSO) : A Medidata customer since 2013, the Seoul-based pharmaceutical company is expanding its technology partnership with Medidata, becoming the first Korean company to incorporate the Medidata Clinical Cloud into all clinical trials across its drug development programs. Check out article Well-Oiled Machine for lube safety tips good health, Dr. So, when the pathogen like him comes in wearing that blue necktie, we destroy him, that’s the concept. clinical sites. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (719) 325-2244 (preferred), or (888) 510-1765 (toll-free), and reference confirmation code 5713887.
Vical Reports Second Quarter 2014 Financial Results and Progress in Key Development Programs

ASP0113 is a therapeutic vaccine to prevent CMV reactivation in hematopoietic stem cell transplant (HCT) subjects and solid organ transplant subjects. Astellas is actively recruiting for three clinical trials of ASP0113: a multinational Phase 3 registration trial in approximately 500 HCT recipients, a multinational Phase 2 trial in approximately 140 kidney transplant recipients, and a Phase 1 pharmacokinetics and immunogenicity trial in dialysis patients in the U.S. Vical will conduct a conference call and webcast today, July 31, at noon Eastern Time, to discuss the company’s financial results and program updates with invited participants. The call and webcast are open on a listen-only basis to any interested parties. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (719) 785-1765 (preferred), or (888) 461-2024 (toll-free), and reference confirmation code 1550995. A replay of the call will be available for 48 hours beginning about two hours after the call. To date, Novirin is the only natural antiviral product on the market with published clinical studies that support its claims.

The morbidity produced by these acute and recurrent infections as outlined below produce much human suffering for which there remains an unmet need for control by effective immunization or antiviral therapy. For further information, contact Vical’s Investor Relations department by phone at (858) 646-1127 or by e-mail at ir@vical.com. We reported financial results this morning for the fourth quarter 2014 which reflects tenured advancement in our HSV-2 program as well as an increase in our collaborative efforts related to our CMV program license to Astellas. The addition of Vaxfectin(R) to the influenza vaccines substantially increased both antibody and T-cell responses compared with nonadjuvanted vaccines in mice and guinea pigs. It has been reported that 25% of congenitally infected infants whose mother had a primary HCMV infection during pregnancy had at least one sequela, compared with 8% in infants born to women with recurrent infection [11]. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 7863802. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs.

Additional information on Vical is available at www.vical.com. This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include net cash use guidance, as well as anticipated developments in independent and collaborative programs, including the initiation and completion of clinical trials. These forward-looking statements represent the company’s judgment as of the date of this release. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. The company disclaims, however, any intent or obligation to update these forward-looking statements.

You may also like